Cyclo Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Cyclo Therapeutics, Inc. carries a market capitalization of 23.59M, placing it among publicly traded companies globally. Its enterprise value stands at 33.88M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 23.59M |
| Enterprise Value | 33.88M |
Share Statistics
Cyclo Therapeutics, Inc. currently has 28.70M shares outstanding.
| Shares Outstanding | 28.70M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 25.96, and the price-to-book ratio stands at -0.22.
| PE Ratio | N/A |
| PS Ratio | 25.96 |
| PB Ratio | -0.22 |
| P/TBV Ratio | -1.68 |
| P/FCF Ratio | -1.00 |
| P/OCF Ratio | -1.00 |
Enterprise Valuation
| EV / Sales | 38.91 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Cyclo Therapeutics, Inc. maintains a current ratio of 0.17, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.17 |
| Quick Ratio | 0.06 |
| Debt / Equity | -90.59 |
| Debt / EBITDA | -0.49 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -457.10 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.26 |
Stock Price Statistics
Cyclo Therapeutics, Inc.'s stock has declined approximately -44.13953% over the past 52 weeks. The 50-day moving average sits at 0.80, while the 200-day moving average is 0.83.
| Beta (5Y) | N/A |
| 52-Week Price Change | -44.13953% |
| 50-Day Moving Average | 0.80 |
| 200-Day Moving Average | 0.83 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Cyclo Therapeutics, Inc. generated 870,725.00 in revenue and converted that into -24.80M in net income, yielding earnings per share of -0.87. EBITDA reached -24.67M, while operating income came in at -24.68M.
| Revenue | 870,725.00 |
| Gross Profit | 813,228.00 |
| Operating Income | -24.68M |
| Pretax Income | -24.80M |
| Net Income | -24.80M |
| EBITDA | -24.67M |
| EBIT | -24.68M |
| Earnings Per Share (EPS) | -0.87 |
Balance Sheet
Cyclo Therapeutics, Inc. holds 928,010.00 in cash and equivalents against 12.21M in total debt, resulting in a net debt position of 11.25M. Total book value stands at -103.01M, with working capital of -15.46M providing operational flexibility.
| Cash & Cash Equivalents | 928,010.00 |
| Total Debt | 12.21M |
| Net Debt | 11.25M |
| Equity (Book Value) | -103.01M |
| Book Value Per Share | -3.60 |
| Working Capital | -15.46M |
Cash Flow
Cyclo Therapeutics, Inc. produced -22.52M in operating cash flow over the past twelve months. After subtracting -2,420.00 in capital expenditures, free cash flow totaled -22.52M - equivalent to -0.79 per share.
| Operating Cash Flow | -22.52M |
| Capital Expenditures | -2,420.00 |
| Free Cash Flow | -22.52M |
| FCF Per Share | -0.79 |
Margins
Cyclo Therapeutics, Inc. operates with a gross margin of 93.40, reflecting its pricing power and cost economics. The operating margin of -2,834.06 and net profit margin of -2,848.16 provide insight into operational efficiency.
| Gross Margin | 93.40 |
| Operating Margin | -2,834.06 |
| Pretax Margin | -2,848.16 |
| Profit Margin | -2,848.16 |
| EBITDA Margin | -2,832.76 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -95.75 |
| FCF Yield | -99.60 |
Stock Splits
Cyclo Therapeutics, Inc.'s most recent stock split took place on December 9, 2020 with a 100:1 split ratio.
| Last Split Date | 12/9/2020 |
| Split Ratio | 100:1 |
Scores
Cyclo Therapeutics, Inc. posts an Altman Z-Score of -45.59, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -45.59 |